Regenxbio (RGNX) Cash from Operations (2014 - 2025)

Regenxbio's Cash from Operations history runs 12 years deep, the most recent figure standing at 52290000.0 for Q4 2025.

• In Q4 2025, Cash from Operations fell 65.35% year-over-year to 52290000.0; the TTM figure through Dec 2025 stood at 123963000.0 (up 28.4% YoY), while the FY2025 annual figure was 123963000.0, up 28.4% from the prior year.
• Cash from Operations for Q4 2025 stood at 52290000.0, up from 55960000.0 in the prior quarter.
• The five-year high for Cash from Operations was 341497000.0 in Q4 2021, with the low at 80918000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 46409500.0 (2023), against an average of 25205400.0.
• The sharpest annual moves came in 2021 and 2022: Cash from Operations surged 765.25% in 2021, then slumped 111.53% in 2022.
• Regenxbio's Cash from Operations stood at 341497000.0 in 2021, then plunged by 111.53% to 39372000.0 in 2022, then retreated by 3.53% to 40760000.0 in 2023, then gained by 22.41% to 31624000.0 in 2024, then plunged by 65.35% to 52290000.0 in 2025.
• Business Quant data shows RGNX's Cash from Operations at 52290000.0 in Q4 2025, 55960000.0 in Q3 2025, and 49342000.0 in Q2 2025.